IDRAPRIL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C11H18N2O5
Molecular Weight	258.271
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(CC(=O)NO)C(=O)[C@@H]1CCCC[C@@H]1C(O)=O

InChI

InChIKey=QKIVRALZQSUWHH-SFYZADRCSA-N

InChI=1S/C11H18N2O5/c1-13(6-9(14)12-18)10(15)7-4-2-3-5-8(7)11(16)17/h7-8,18H,2-6H2,1H3,(H,12,14)(H,16,17)/t7-,8+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C11H18N2O5
Molecular Weight	258.271
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7893583 | https://www.ncbi.nlm.nih.gov/pubmed/8641320

Idrapril is an inhibitor of the angiotensin-converting enzyme the last is responsible for recurrent myocardial infarction in patients with left ventricular dysfunction. Idrapril participated in phase II clinical trials in essential hypertensive patients, where was shown that the drug was well tolerated. In addition, it was involved in preclinical studies as a potential drug to treat heart failure and postmyocardial infarction. However, the development of the drug was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Alteration of cytochrome P-450 isozymes by captopril and idrapril in hepatic and renal microsomes of normotensive and spontaneously hypertensive rats.	1997-07	9268216
Angiotensin-converting enzyme inhibition by hydroxamic zinc-binding idrapril in humans.	1994-08	7526067
Oral pharmacokinetics and pharmacodynamics of idrapril calcium, the prototype of a new class of angiotensin converting enzyme inhibitors, in humans.	1993-12	8158413
Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.	1993-09-01	7902245
Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors.	1992-07	1383623

Sample Use Guides

In Vivo Use Guide

in 8 healthy men: Increasing doses of 1, 5, and 25 mg idrapril as well as placebo or 5 mg captopril were administered intravenously (i.v.) at 1-week intervals. oral: healthy volunteers after multiple dosing for 5 days at the doses of 100, 200 and 400 mg twice daily.

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:44:21 GMT 2025` Edited by `admin` on `Mon Mar 31 18:44:21 GMT 2025`
Record UNII	176P5C4QU8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IDRAPRIL

Official Name

English

Idrapril [WHO-DD]

Preferred Name

English

(1S,2R)-2-(((HYDROXYCARBAMOYL)METHYL)METHYLCARBAMOYL)CYCLOHEXANECARBOXYLIC ACID

Systematic Name

English

idrapril [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C247